Merck sought leave to appeal a decision of the Federal Court of Appeal (2021 FCA 224) affirming a Federal Court decision upholding Health Canada’s refusal to add a patent relating to a formulation of Merck’s KEYTRUDA, a biologic drug containing pembrolizumab, to the Patent Register.
On May 12, 2022, the Supreme Court of Canada denied leave to Merck (Merck Canada Inc v Minister of Health, Docket No. 40043).
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
FCA finds Teva would directly infringe and induce infringement of Janssen’s paliperidone palmitate patent
As previously reported, the Federal Court found that Teva would directly infringe but not induce infringement of certain claims of Canadian Patent No. 2,655,335 (335 patent) regarding its paliperidone...Read More -
Supreme Court of Canada denies Apotex leave to appeal ONCA olanzapine Statutes of Monopolies decision
Eli Lilly had successfully obtained an order of prohibition against Apotex relating to Canadian Patent No. 2,041,113, which was later found invalid in a decision involving Novopharm (affirmed on appea...Read More -
Apotex’s section 8 claim for Apo-Atomoxetine dismissed
On March 30, 2023, the Ontario Superior Court of Justice dismissed Apotex’s claim under section 8 of the Patented Medicines (Notice of Compliance) Regulations relating to Apo-Atomoxetine (Lilly’s STRA...Read More